gpt-dict.com

Green Tea Extract for Cardiovascular Disease

Verdict: Modest biomarker effect; no proof it prevents cardiovascular events

Green tea extract produces small, real improvements in cholesterol and blood pressure, but no randomized trial shows it prevents heart attacks, strokes, or cardiovascular death; the only hard-outcome benefit comes from people who drank brewed tea, not from extract capsules. As a supplement it rates weak (Tier C) and carries a real liver-injury caution.

C 🟠 C Weak Evidence Published with Warning

🔬Why this grade7-layer evidence engine

The grade is weak because the evidence is split between surrogate markers and hard outcomes. Two RCT meta-analyses confirm a genuine but small biomarker effect: a 55-trial analysis (PMID 36704803, n=4,874) found total cholesterol down about 7.6 mg/dL, LDL down about 5.8 mg/dL, and diastolic blood pressure down under 1 mmHg, while a 20-trial analysis (PMID 24675010, n=1,536) found systolic blood pressure down roughly 2 mmHg. These are modest compared with statins or blood-pressure drugs, and a small null RCT (PMID 22144918) found no change in any risk factor.

Crucially, no trial has tested green tea EXTRACT against real cardiovascular events. The only mortality signal (CVD mortality RR 0.86) comes from a meta-analysis of 38 observational cohorts of tea DRINKERS (PMID 38938012, ~1.96M people), which is vulnerable to confounding and does not transfer to concentrated capsules. US FDA recognizes green tea catechin only as a GRAS food antioxidant, not an approved heart therapy, and WHO/IARC classifies tea as Group 3 (not classifiable for carcinogenicity).

Clinical sources reinforce the caution. Mayo Clinic states the potential benefits 'seem to be in the cup, not in supplements or tea extract capsules,' and neither cardiology guidelines endorse it. A safety overhang weighs the grade down: a USP review (PMID 32140423) links concentrated extract to idiosyncratic liver injury (HLA-B*35:01-associated), and UK COT/NHS affirm the EFSA threshold that EGCG at or above 800 mg/day from supplements is tied to liver damage, with brewed tea posing no such hazard.

⚖️

Scoring transparency

All scores computed by a 7-layer evidence engine — fully auditable
Raw score 0.45
D
C
B
A
S
← counter-evidence / ineffectiveeffective / strong evidence →
Final grade
C · Published with Warning
Confidence
75%
Broadly consistent
Evidence level
E2
Multiple high-quality MAs (≥2 independent, consistent)

How strongly each layer supports this effect

lower = less supportive
L5 Clinical bodiesAuthoritative stance
0.40
L2 PubMedPrimary literature
0.45
L3 MechanismPlausibility
0.45
L1 ExamineGlobal benchmark
0.50
L11 AI re-checkIndependent read
0.50
Against Mixed Supports
▸View the full decision path (audit trail)
  1. compute_raw_score — 加權公式: L2×0.30 + L3×0.25 + L5×0.25 + L11×0.10 + L1×0.10 = 0.448
  2. tier_from_score — 依分數區間映射至 tier letter
  3. apply_hec_rules — 高品質 SR/MA 顯示 positive (1 篇 > 0 negative)
  4. tier_strict_requirement_check — Tier 條件達標，未降階
  5. detect_disputes — 偵測到 0 個 hard + 0 個 soft dispute
  6. decide_status — 依 tier + dispute 結果決定 status

📄PubMed studies (5)L2 · primary research & systematic reviews

The effects of green tea supplementation on cardiovascular risk factors: A systematic review and meta-analysis
PMID: 36704803 2023 統合分析 n = 4,874
Finding: Green tea supplementation significantly reduced total cholesterol (WMD -7.62 mg/dL, 95% CI -10.51 to -4.73, p<0.001), LDL-C (WMD -5.80 mg/dL, 95% CI -8.30 to -3.30, p<0.001) and DBP (WMD -0.87 mmHg, 95% CI -1.45 to -0.29, p=0.003), and raised HDL (WMD +1.85 mg/dL, p=0.010). Triglycerides and SBP were not significantly improved.
Effect size: WMD TC -7.62 mg/dL; LDL -5.80 mg/dL; HDL +1.85 mg/dL; DBP -0.87 mmHg; TG NS; SBP NS
View on PubMed
The effect of green tea on blood pressure and lipid profile: a systematic review and meta-analysis of randomized clinical trials
PMID: 24675010 2014 統合分析 n = 1,536
Finding: Green tea intake produced significant reductions in SBP (-1.94 mmHg, 95% CI -2.95 to -0.93), total cholesterol (-0.13 mmol/L, 95% CI -0.20 to -0.07) and LDL-C (-0.19 mmol/L, 95% CI -0.30 to -0.09). The SBP effect was characterized as small; the cholesterol effects as moderate.
Effect size: MD SBP -1.94 mmHg; TC -0.13 mmol/L; LDL -0.19 mmol/L
View on PubMed
Tea consumption and risk of all-cause, cardiovascular disease, and cancer mortality: a meta-analysis of thirty-eight prospective cohort data sets
PMID: 38938012 2024 統合分析 n = 1,956,549
Finding: Highest versus lowest tea consumption was associated with lower cardiovascular mortality (RR 0.86, 95% CI 0.79 to 0.94); moderate consumption (~1.5-2.0 cups/day) showed the lowest all-cause, CVD and cancer mortality. This is observational evidence on tea DRINKING, not extract supplementation.
🟠 Limited quality Effect size: RR CVD mortality 0.86 (highest vs lowest tea intake)
View on PubMed
Randomized controlled trial for an effect of catechin-enriched green tea consumption on adiponectin and cardiovascular disease risk factors
PMID: 22144918 2011 隨機對照試驗 n = 51
Finding: No significant difference between high- and low-catechin groups for adiponectin change (0.35 ug/mL, 95% CI -1.03 to 1.74) or for any measured CVD risk factor. A small null trial that tempers extrapolation from surrogate-marker meta-analyses.
🟠 Limited quality Effect size: Adiponectin change 0.35 ug/mL (NS); no CVD risk factor difference
View on PubMed
United States Pharmacopeia (USP) comprehensive review of the hepatotoxicity of green tea extracts
PMID: 32140423 2020 Other
Finding: Concentrated green tea extract has been associated with idiosyncratic hepatotoxicity; case reports link liver injury to EGCG intakes of ~140-1000 mg/day with marked inter-individual susceptibility (HLA-B*35:01 association). Drinking brewed green tea is NOT associated with liver injury - the hazard is specific to concentrated extract.
Effect size: Transaminase/cholestasis elevation in 9 of 38 intervention studies at >=800 mg/day EGCG
View on PubMed

🏛️Regulatory & authoritative positionsL4/L5 · FDA / EMA / NIH ODS / Cochrane / Mayo …

L4a US FDA
Cautious
Oil-soluble green tea extract (green tea catechin palmitate) is considered Generally Recognized as Safe (GRAS) based on scientific procedures as an antioxidant in food source↗
L4b EU EFSA
Against
L4c UK NHS
Cautious
The COT concluded that there are no new data to suggest that EFSA's conclusion, that 800 mg/day EGCG was probably safe, is inappropriate. Although no new studies identified any effects of EGCG in humans at doses below 800 mg/day, the possibility cannot be excluded that a few individuals could still experience adverse effects below this dose due to an idiosyncratic reaction. source↗
L4d TW TFDA / 衛福部
Neutral
建議成人每人每天攝取兒茶素EGCG上限為800毫克，不應過量；一般沖泡綠茶飲用的民眾不必太過擔心兒茶素傷肝問題。 source↗
L5a NIH Office of Dietary Supplements
Cautious
L5b Mayo Clinic
Cautious
The potential benefits seem to be in the cup, not in supplements or tea extract capsules. So far, there's no certainty that the compounds in supplements are the same ones in tea, and even less certainty that these supplements might provide the same potential health benefits as tea. source↗
L5c Cleveland Clinic
Cautious
L5d Harvard Health
Cautious
L5e Specialty Society (condition-mapped)
Not addressed
✓PMID 100% verifiedevery citation checked via NCBI Entrez
🔬5 PubMed studiesindependently re-checked by multiple sub-agents
engine_version: v1.0 claim_id: CLM-COND-cardiovascular-disease-INT-green-tea-extract-001 繁體中文版 →